One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand treatment to others.

After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years. On February 12, CRISPR Therapeutics announced its financial results for 2025, highlighting a period of significant commercial ...

Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...

Rapid advancements in CRISPR and next-generation gene editing technologies, combined with a strong clinical pipeline ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.

Developing a gene therapy typically takes years, but when Baby KJ was diagnosed with a deadly genetic condition, scientists had only months. What followed was a successful collaboration among ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.